Quva Pharma, Inc.

Quva Pharma, Inc., a for-profit 503B outsourcing facility based in Sugar Land, Texas, manufactures and delivers sterile compounded pharmaceutical products to federal healthcare agencies as a prime contractor (100% of recent awards), competing in full and open competition with no set-aside posture. The vendor's narrow, specialized capability — patient-controlled analgesia systems, epidural products, sterile intravenous preparations, and other compounded pain-management pharmaceuticals — serves federal medical and clinical research needs exclusively through direct purchase orders and delivery orders rather than through broader IT or supply-chain vehicles.

Quva Pharma's customer concentration is singular: the National Institutes of Health Clinical Center accounts for 11 of 18 awards and $2.6 million of the $3.6 million combined potential value (100% portfolio coverage). The vendor also holds smaller contract positions with the Department of the Army Medical Command (5 awards, $361 thousand), the Defense Health Agency (1 award, $545 thousand), and the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 21 (1 award, $52 thousand). The NIH Clinical Center concentration reflects repeated purchase orders and a single-award indefinite delivery contract with a $250 thousand ceiling awarded in December 2024 and expiring September 30, 2025. Recent representative awards include a $110 thousand purchase order from NIH Clinical Center awarded May 26, 2026 for patient-controlled analgesia systems and epidural products (performance through May 25, 2027), a $100 thousand sole-source purchase order from NIH dated February 19, 2025, and a $250 thousand delivery order from NIH dated April 22, 2024. The vendor holds a secondary position on an indefinite delivery contract (75N90019D00030) carrying five task orders and $574 thousand combined potential value.

Activity is sparse and episodic: two awards in 2022, three in 2024, one in 2025, and one in 2026, across an eighteen-year source window. Only one award ($110 thousand) reaches completion within the next twenty-four months. With $1.7 million obligated against $3.6 million potential value, the vendor has invoiced approximately 48% of ceiling across its portfolio. Quva Pharma operates entirely as a prime contractor with no subcontract footprint; the vendor does not serve as a sub to larger primes. The portfolio sits exclusively under NAICS 325412 (Pharmaceutical Preparation Manufacturing), with PSC codes distributed across Drugs and Biologicals (11 awards) and Medical and Surgical Instruments, Equipment, and Supplies (6 awards). Sole-source determinations recur across NIH Clinical Center awards, reflecting the federal government's characterization of Quva Pharma as the only reasonably available source for its specialized sterile compounding capabilities in federal healthcare settings.